Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study

• DOI: 10.1016/j.ejca.2023.113292
• Publication Date: 2023-08-18T11:52:43Z
• Authors: Edwige Baudry; Natacha Naoun; Edouard Auclin; Carolina Saldana; Philippe Barthelemy; Lionnel Geoffrois; Constance Thibault; Manon de Vries-Br...; Delphine Borchiel...; Denis Maillet; Laure Hirsch; Charles Vauchier; Lucia Carril-Ajuria; Emeline Colomba; Alice Bernard-Tes...; Bernard Escudier; Ronan Flippot; Laurence Albigès
• Keywords: Cabozantinib; Clinical endpoint

Despite metastatic renal cell carcinoma (mRCC) expanded treatment options, disease progression ultimately occurs for most patients. Rechallenge may be a compelling strategy in a refractory setting. Cabozantinib is the standard of care in first and later lines of therapy, but its activity in rechallenge is unknown.This retrospective study assessed the efficacy and safety of cabozantinib rechallenge, as defined by a second exposure after an interval of ≥3 months without treatment or ≥1 other treatment line, in patients with mRCC. The primary endpoint was median progression-free survival (PFS) at rechallenge. Secondary endpoints included overall survival, objective response rate, and safety at rechallenge.We included 51 mRCC patients who received cabozantinib in a rechallenge setting between 2017 and 2022. Median age at diagnosis was 54 years, 78% were male, 90% had clear cell mRCC, and 92% had prior nephrectomy. 15 patients (29%) were rechallenged after a pause in treatment, whereas 36 (70.6%) had ≥1 other treatment lines between first cabozantinib exposure (CABO-1) and rechallenge (CABO-2). Median PFS was 15.1 months (mo, 95% Confidence interval 11.2-22.1) at CABO-1 and 14.4mo (95%CI 9.8-NR) at CABO-2. Median overall survival was 67.6mo for CABO-1 (95% CI 52.2-NR) and 27.4mo for CABO-2 (95%CI 17.2-NR); objective response rate was 70.6% for CABO-1 and 60% for CABO-2. CABO-2 PFS was higher for patients with CABO-1 PFS > 12 months, and for those who discontinued CABO-1 because of toxicity, without statistical significance. There were no unexpected adverse events.Cabozantinib rechallenge is a feasible treatment option with potential clinical benefit for mRCC patients.